Ranibizumab
Ranibizumab
- CAS:
- 347396-82-1
- MF:
- C11H12N2O2
- MW:
- 204.22518
Suppliers by country/region
Company Type
Properties
- form
- Liquid
- color
- Colorless to light yellow
Safety Information
Use
Ranibizumab is a recombinant, humanized, IgG1 monoclonal antibody fragment (Fab) that neutralizes all active forms of vascular endothelial growth factor A (VEGF-A), and it is indicated for the treatment of neovascular age-related macular degeneration (AMD). It consists of a nonbinding human sequence and a high-affinity binding epitope (Fab fragment) derived from the mouse. The full-length RhuMab VEGF (bevacizumab) was launched previously by Genentech for the treatment of colorectal cancer. Both the antibody fragment and the full-length antibody bind to and inhibit all active forms of VEGF-A and are derived from the same mouse monoclonal antibody. However, ranibizumab has been genetically engineered through a process of selective mutation to increase its affinity for binding and inhibiting the growth factor.
0 India supplier list of "Ranibizumab"
- Product Name:Ranibizumab
- Products Intro:Purity: 99% | Package: 1kg
- Company Type: Trader
- Country/Region: CHINA
$0.00/ 1kg
- Product Name:Ranibizumab (anti-VEGFA)
- Products Intro:Purity: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I | Package: $149.9/100μg;$719.9/1mg;$1799.9/5mg;$2879.9/10mg;Bulk package | CustNote: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1-CH1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- Company Type: Trader
- Country/Region: UNITED STATES
- Main Products: Chemicals and BioChemicals,Materials Science,ligands acting on targets,Proteins,Antibodies